Compare Cigna Corp (CI) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Marvell Technology Inc — how do they compare? Cigna Corp trades at $302.09 (market cap $80.55B), while Marvell Technology Inc trades at $224.71 (market cap $190.94B). The key difference: Marvell Technology Inc is far larger — about 2.4× Cigna Corp's market cap, and Cigna Corp pays the higher dividend (2.05%). Which is the better fit depends on your goals.
| CI | MRVL | |
|---|---|---|
Market Cap | $80.55B | $190.94B |
Sector | Health | Technology |
52-Week High | $311.00 | $316.43 |
52-Week Low | $244.41 | $62.31 |
Enterprise Value | $103.65B | $192.37B |
Dividend Yield | 2.05% | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $304.50, up 3.76% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.91 and P/S of 0.29. Recent news highlights strategic AI investments in pharmacy services and positive sector sentiment.
The investment case centers on undervaluation, earnings momentum, and dividend yield, though risks include regulatory challenges and moderating cash flow. With a consensus price target of $339.82 implying 11.6% upside, Wall Street maintains a bullish stance, but investors should weigh execution risks against growth initiatives.
Marvell Technology (MRVL) trades at $217.53, down 7.75% over the past day, reflecting recent market volatility. The stock shows strong analyst support with an 82% buy rating and a consensus price target of $275.68, indicating significant upside potential. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.80 surpassing the $0.798 estimate. However, the company reported a net loss of $885 million for 2025, though revenue grew to $5.77 billion. Technical indicators are bearish, with the price near key support at $213.
The outlook for MRVL is positive due to its positioning in custom AI chips and optical networking, with projected revenue growth to $8.7 billion in 2026. Risks include high valuation multiples (P/E of 74.75) and competitive pressures from peers like Nvidia and Broadcom. Investors should weigh the strong analyst optimism against fundamental challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
